{{noteTA
|G1=Medicine
|G2=Country
}}
{{Infobox drug
| drug_name          = AD5-nCOV
| type               = vaccine
| image              = CanSino Convidecia.jpg
| alt                = 
| caption            = 一瓶在墨西哥分包装生产的克威莎疫苗

<!-- Vaccine data -->
| target             = [[严重急性呼吸系统综合征冠状病毒2|严重急性呼吸系统综合征冠状病毒2]]（SARS-CoV-2）
| vaccine_type 	     = viral

<!-- Clinical data -->
| pronounce          = 
| tradename          = 克威莎（Convidecia）
| Drugs.com          = 
| MedlinePlus        = 
| licence_EU         = 
| licence_US         = 
| pregnancy_AU       = <!-- A/B1/B2/B3/C/D/X -->
| pregnancy_category = 
| legal_AU           = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU_comment   = 
| legal_BR           = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F-->
| legal_BR_comment   = 
| legal_CA           = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK           = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US           = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_UN           = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_NZ           = <!--Class A, B, C -->
| legal_status       = 全面授权：中国大陆<br>[[緊急使用授權|緊急使用授權]]：匈牙利、墨西哥、马来西亚、巴基斯坦、智利、世界卫生组织
| routes_of_administration = [[肌肉注射|肌肉注射]]、{{le|噴鼻劑|Nasal spray}}（试验中）
<!-- Identifiers -->
| CAS_number         = 
| ATCvet             = 
| ATC_prefix         = None <!-- scheduled to be J07BX03 in 2022 -->
| ATC_suffix         = 
| PubChem            = 
| DrugBank           = DB15655
}}
'''Ad5-nCoV'''，商品名为'''克威莎'''（Convidecia），是由[[康希诺生物|康希诺生物]]股份公司和[[中国人民解放军军事科学院军事医学研究院|中国人民解放军军事科学院军事医学研究院]]生物工程研究所开发的单针接种<ref name=":22">{{Cite web|title=It's not just Johnson & Johnson: China has a single-dose COVID-19 vaccine that's 65% effective|url=https://fortune.com/2021/02/09/china-covid-vaccine-single-dose-cansino-johnson-johnson/|access-date=2021-02-11|work=Fortune|archive-date=2021-05-15|archive-url=https://web.archive.org/web/20210515022135/https://fortune.com/2021/02/09/china-covid-vaccine-single-dose-cansino-johnson-johnson/|dead-url=no}}</ref>[[2019冠状病毒病疫苗|2019冠状病毒病疫苗]]，该疫苗采用重组5型腺病毒载体，2020年下半年进入Ⅲ期临床试验阶段。Ad5-nCoV为[[陈薇|陈薇]]团队研发的新冠疫苗，是目前中华人民共和国批准上市的COVID-19疫苗中，唯一可采用单针接种程序的疫苗<ref>{{Cite web|title=国内首个单针接种的新冠疫苗获批上市|url=https://www.bjnews.com.cn/detail/161434174815958.html|accessdate=2021-02-26|work=新京报 - 好新闻，无止境|archive-date=2021-04-23|archive-url=https://web.archive.org/web/20210423024214/https://www.bjnews.com.cn/detail/161434174815958.html|dead-url=no}}</ref>。克威莎与[[牛津－阿斯利康2019冠状病毒病疫苗|牛津－阿斯利康2019冠状病毒病疫苗]]和[[加马列亚2019冠状病毒病疫苗|加马列亚2019冠状病毒病疫苗]]同为腺病毒载体疫苗<ref name=":32">{{cite news|date=2020-06-10|title=Coronavirus Vaccine Tracker|work=The New York Times|url=https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html|access-date=2020-12-12|issn=0362-4331|vauthors=Zimmer C, Corum J, Wee SL|archive-date=2020-12-24|archive-url=https://web.archive.org/web/20201224200821/https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html|dead-url=no}}</ref>，与mRNA疫苗相比，克威莎可以在不太严寒的条件下保存<ref name=":4">{{Cite news|last1=Constable|first1=Pamela|last2=Hussain|first2=Shaiq|title=Defying fears and skepticism, thousands in Pakistan volunteer for Chinese vaccine trials|work=Washington Post|url=https://www.washingtonpost.com/world/asia_pacific/pakistan-coronavirus-vaccine/2020/12/31/b2582d5e-4843-11eb-a9f4-0e668b9772ba_story.html|access-date=2021-01-01|issn=0190-8286|archive-date=2021-02-04|archive-url=https://web.archive.org/web/20210204070302/https://www.washingtonpost.com/world/asia_pacific/pakistan-coronavirus-vaccine/2020/12/31/b2582d5e-4843-11eb-a9f4-0e668b9772ba_story.html|dead-url=no}}</ref><ref name=":72"/>。

2021年2月，来自三期临床试验和101例COVID-19病例的全球数据表明，该疫苗在预防COVID-19的中度症状方面有65.7%的有效率，在预防严重疾病方面有91%的有效率<ref name=":82">{{Cite web|date=8 February 2021|title=CanSinoBIO's COVID-19 vaccine 65.7% effective in global trials, Pakistan official says|url=https://www.reuters.com/article/us-health-coronavirus-vaccine-pakistan/cansinobios-covid-19-vaccine-657-effective-in-global-trials-pakistan-official-says-idUSKBN2A81N0|access-date=2021-02-08|publisher=Reuters|archive-date=2021-03-24|archive-url=https://web.archive.org/web/20210324225256/https://www.reuters.com/article/us-health-coronavirus-vaccine-pakistan/cansinobios-covid-19-vaccine-657-effective-in-global-trials-pakistan-official-says-idUSKBN2A81N0|dead-url=no}}</ref>。2021年12月，其国际三期临床试验结果的更新在[[柳叶刀_(杂志)|《柳叶刀》]]发表，该疫苗在预防COVID-19症状方面总体有效率约为57.5%。<ref>[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02753-7/fulltext Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial]</ref>

该疫苗与[[強生2019冠狀病毒病疫苗|强生COVID-19疫苗]]的有效率相近，强生疫苗是另一款采用单针接种程序的腺病毒载体疫苗，在全球范围内的有效率为65.7%<ref name=":72">{{Cite news|date=2021-02-08|title=China's CanSino Covid Vaccine Shows 65.7% Efficacy|work=Bloomberg.com|url=https://www.bloomberg.com/news/articles/2021-02-08/pakistan-says-cansino-s-covid-vaccine-shows-65-7-efficacy|access-date=2021-02-10|archive-date=2021-06-22|archive-url=https://web.archive.org/web/20210622201641/https://www.bloomberg.com/news/articles/2021-02-08/pakistan-says-cansino-s-covid-vaccine-shows-65-7-efficacy|dead-url=no}}</ref><ref name=":22"/>。其单针接种程序和冷藏储存要求（2至8摄氏度），可使其成为许多国家和地区的理想疫苗选择<ref name=":72" />。预计到2021年底，疫苗的生产能力将达到5亿剂<ref name=":16">{{Cite web|title=China can hit 500-mln-dose annual capacity of CanSinoBIO COVID-19 vaccine this year|url=https://finance.yahoo.com/news/china-hit-500-mln-dose-103509138.html|access-date=2021-02-28|work=finance.yahoo.com|archive-date=2021-05-01|archive-url=https://web.archive.org/web/20210501095646/https://finance.yahoo.com/news/china-hit-500-mln-dose-103509138.html|dead-url=no}}</ref>。[[世卫组织|世卫组织]]于2022年5月19日向康希诺发出该种疫苗的紧急使用授权。<ref name="marketwatch20220519">{{Cite web |url=https://www.marketwatch.com/story/who-adds-cansinos-covid-19-vaccine-to-list-of-validated-shots-2022-05-19 |title=WHO adds CanSino's COVID-19 vaccine to list of validated shots |access-date=2022-05-20 |archive-date=2022-05-19 |archive-url=https://web.archive.org/web/20220519181545/https://www.marketwatch.com/story/who-adds-cansinos-covid-19-vaccine-to-list-of-validated-shots-2022-05-19 }}</ref>

==研发历史==
===肌注剂一、二期临床试验===
2020年年初，[[中国人民解放军军事医学科学院|中国人民解放军军事医学科学院]][[中国人民解放军军事科学院军事医学研究院|军事医学研究院]]生物工程研究所院士[[陈薇|陈薇]]团队于1月26日（正月初二）进驻[[武汉|武汉]]，协助加快[[2019冠状病毒病检测|检测和确诊]]速度，并表示要在12周内研制出[[2019冠状病毒病疫苗|疫苗]]。<ref>{{cite news|title=军队专家组深入疫区进行科研攻关|location=北京|publisher=解放军报|url=http://www.81.cn/jfjbmap/content/2020-01/31/content_253028.htm|date=2020-01-31|author=孙兴维,张振威|archiveurl=https://web.archive.org/web/20200221120706/http://www.81.cn/jfjbmap/content/2020-01/31/content_253028.htm|archivedate=2020-02-21|dead-url=no|accessdate=2021-04-08}}</ref><ref>{{cite web|title=疫情拐点将到？陈薇院士：最坏打算，最充分方案，最长期奋战！|url=http://news.sciencenet.cn/htmlnews/2020/2/435299.shtm|author=李晨阳|date=2020-02-01|publisher=中国科学报社|archiveurl=https://web.archive.org/web/20200221120752/http://news.sciencenet.cn/htmlnews/2020/2/435299.shtm|archivedate=2020-02-21|dead-url=no|access-date=2021-04-08}}</ref>陈薇院士团队与[[康希诺生物|康希诺生物]]合作研制的Ad5-nCoV疫苗于3月16日获批进入临床试验<ref>{{cite news|title=重组新冠疫苗获批启动临床试验|location=北京|publisher=解放军报|url=http://www.81.cn/jfjbmap/content/2020-03/18/content_256774.htm|date=2020-03-18|author=孙兴维,邵龙飞|accessdate=2020-04-18|archiveurl=https://web.archive.org/web/20200720104043/http://www.81.cn/jfjbmap/content/2020-03/18/content_256774.htm|archivedate=2020-07-20|dead-url=no}}</ref>。该试验在湖北省武汉市的两个医疗机构中，对108位年龄在18至60岁的健康成年人进行了研究<ref name="chinadaily-2020-03-23">{{cite news|vauthors=Cui J|url=http://covid-19.chinadaily.com.cn/a/202003/23/WS5e77f24aa31012821728112d.html|title=Human vaccine trial gets underway|work=China Daily|date=2020-03-23|access-date=2020-04-18|archive-date=2021-06-05|archive-url=https://web.archive.org/web/20210605074034/https://covid-19.chinadaily.com.cn/a/202003/23/WS5e77f24aa31012821728112d.html|dead-url=no}}</ref>。

2020年4月12日，Ad5-nCoV疫苗进入二期临床试验<ref>{{cite news|title=我国腺病毒载体重组新冠病毒疫苗率先进入二期临床试验|location=北京|publisher=解放军报|url=http://www.81.cn/jfjbmap/content/2020-04/15/content_258974.htm|date=2020-04-15|author=张振威,邵龙飞|accessdate=2020-04-18|archiveurl=https://web.archive.org/web/20200720104731/http://www.81.cn/jfjbmap/content/2020-04/15/content_258974.htm|archivedate=2020-07-20|dead-url=no}}</ref>二期临床试验结果于2020年7月20日发表在[[同行评审|同行评审]]杂志《[[柳葉刀_(雜誌)|-{zh-cn:柳叶刀; zh-tw:刺胳針; zh-hk:刺針; zh-sg:柳叶刀}-]]》上，并根据对508位合格参与者的数据进行统计分析，注意到中和抗体和T细胞反应<ref>{{Cite journal|title=Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial|url=https://linkinghub.elsevier.com/retrieve/pii/S0140673620316056|last=Zhu|first=Feng-Cai|last2=Guan|first2=Xu-Hua|date=2020-08-XX|journal=The Lancet|issue=10249|doi=10.1016/S0140-6736(20)31605-6|volume=396|pages=479–488|language=en|pmc=PMC7836858|pmid=32702299|last3=Li|first3=Yu-Hua|last4=Huang|first4=Jian-Ying|last5=Jiang|first5=Tao|last6=Hou|first6=Li-Hua|last7=Li|first7=Jing-Xin|last8=Yang|first8=Bei-Fang|last9=Wang|first9=Ling|access-date=2021-05-09|archive-date=2021-06-17|archive-url=https://web.archive.org/web/20210617233523/https://linkinghub.elsevier.com/retrieve/pii/S0140673620316056|dead-url=no}}</ref>。9月，[[中国疾病预防控制中心|中国疾病预防控制中心]]首席科学家[[曾光_(1946年)|曾光]]表示，一期临床试验后的六个月，受试者的COVID-19抗体含量仍然很高。他表示，尽管仍需要进行三期临床试验，但高水平的抗体表明，疫苗可能会在较长的时间内提供免疫力<ref>{{cite web|author=O'Brien E|date=2020-09-25|title=Covid Antibodies Endure Over Six Months in China Trial Subjects|url=https://www.bloomberg.com/news/articles/2020-09-25/covid-antibodies-endure-over-six-months-in-china-trial-subjects|access-date=2020-09-29|work=www.bloomberg.com|archive-date=2020-10-14|archive-url=https://web.archive.org/web/20201014230451/https://www.bloomberg.com/news/articles/2020-09-25/covid-antibodies-endure-over-six-months-in-china-trial-subjects|dead-url=no}}</ref>。9月24日，康希诺生物开始对481名参与者进行IIb期临床试验，以评估Ad5-nCoV对6-17岁儿童和56岁及以上老年人的安全性和免疫原性<ref>{{cite web|title=Phase IIb Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) - Full Text View - ClinicalTrials.gov|url=https://clinicaltrials.gov/ct2/show/NCT04566770|access-date=2020-10-21|work=clinicaltrials.gov|archive-date=2021-04-10|archive-url=https://web.archive.org/web/20210410012935/https://clinicaltrials.gov/ct2/show/NCT04566770|dead-url=no}}</ref>。

2020年8月11日，Ad5-nCoV疫苗被中华人民共和国[[国家知识产权局|国家知识产权局]]授予发明专利权<ref>{{cite news|url=http://news.ynet.com/2020/08/16/2803023t70.html|title=国内首个！陈薇院士团队新冠疫苗获得专利|work=[[北京青年报|北京青年报]]|date=2020-08-16|accessdate=2020-08-16|archive-date=2021-03-03|archive-url=https://web.archive.org/web/20210303105613/http://news.ynet.com/2020/08/16/2803023t70.html|dead-url=no}}</ref>。

2020年5月16日，加拿大总理[[贾斯汀·特鲁多|贾斯汀·特鲁多]]宣布，[[加拿大卫生部|加拿大卫生部]]已批准由加拿大疫苗学中心（CCfV）对康希诺生物生产的COVID-19疫苗进行二期临床试验。CCfV的负责人斯科特·哈珀林（Scott Halperin）表示，该疫苗并非加拿大唯一进入临床试验的疫苗，所有正在研究中的疫苗只有在三期临床阶段完成后才能公开供应<ref>{{cite news |vauthors=Bogart N |title=Health Canada approves first clinical trial for potential COVID-19 vaccine |url=https://www.ctvnews.ca/health/coronavirus/health-canada-approves-first-clinical-trial-for-potential-covid-19-vaccine-1.4942507 |access-date=2020-09-07 |work=CTV News |date=2020-05-16 |archive-date=2021-02-26 |archive-url=https://web.archive.org/web/20210226193335/https://www.ctvnews.ca/health/coronavirus/health-canada-approves-first-clinical-trial-for-potential-covid-19-vaccine-1.4942507 |dead-url=no }}</ref><ref name="cbc._Cana">{{Cite web |title=Canada's first COVID-19 vaccine trials approved for Halifax university |last=Ryan |first=Haley |publisher=CBC News |date=2020-05-16 |access-date=2021-01-04 |url=https://www.cbc.ca/news/canada/nova-scotia/first-canadian-vaccine-trials-covid-19-halifax-1.5573283 |archive-date=2020-05-22 |archive-url=https://web.archive.org/web/20200522055415/https://www.cbc.ca/news/canada/nova-scotia/first-canadian-vaccine-trials-covid-19-halifax-1.5573283 |dead-url=no }}</ref>。一旦试验成功，加拿大国家研究委员会将与康希诺生物合作，在加拿大生产和分发疫苗<ref name="cbc._Cana"/>。2020年8月，加拿大国家研究委员会披露，该疫苗未经中华人民共和国海关批准运往加拿大。此后，媒体报道称康希诺生物与加拿大疫苗学中心之间的合作被放弃<ref>{{cite news |vauthors=Cooke A |date=2020-08-26 |title=Canadian COVID-19 clinical trial scrapped after China wouldn't ship potential vaccine |url=https://www.cbc.ca/news/canada/nova-scotia/canada-china-covid-19-vaccine-trial-plug-pulled-1.5701101 |work=CBC News |access-date=2020-09-07 |archive-date=2021-03-22 |archive-url=https://web.archive.org/web/20210322153524/https://www.cbc.ca/news/canada/nova-scotia/canada-china-covid-19-vaccine-trial-plug-pulled-1.5701101 |dead-url=no }}</ref>，惟此说法遭到康希诺生物否认<ref>{{cite news |author1=钱童心 |title=康希诺称与加拿大项目尚未完全终结 |url=https://www.yicai.com/news/100752194.html |accessdate=2021-04-07 |work=第一财经 |date=2020-08-28 |archive-date=2021-01-23 |archive-url=https://web.archive.org/web/20210123151533/https://www.yicai.com/news/100752194.html |dead-url=no }}</ref>。

===肌注剂三期临床试验===
2020年8月，沙特阿拉伯确认该疫苗将在利雅得、[[达曼_(沙特阿拉伯)|达曼]]和麦加等城市，对5,000人开展第三阶段试验<ref name=":12">{{cite news|vauthors=Eltahir N|url=https://www.reuters.com/article/us-health-coronavirus-saudi-cansinobio/cansino-to-start-phase-iii-trial-of-covid-19-vaccine-in-saudi-idUSKCN2550L9|title=CanSino to start Phase III trial of COVID-19 vaccine in Saudi|work=Reuters|date=2020-08-09|access-date=2020-08-09|archive-date=2021-06-11|archive-url=https://web.archive.org/web/20210611125740/https://www.reuters.com/article/us-health-coronavirus-saudi-cansinobio/cansino-to-start-phase-iii-trial-of-covid-19-vaccine-in-saudi-idUSKCN2550L9|dead-url=no}}</ref>。

2020年9月，俄罗斯NPO Petrovax对500名志愿者进行三期临床试验<ref name=":5">{{cite web|title=Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19 - Full Text View - ClinicalTrials.gov|url=https://clinicaltrials.gov/ct2/show/NCT04540419|access-date=2020-10-21|work=clinicaltrials.gov|archive-date=2021-04-30|archive-url=https://web.archive.org/web/20210430235050/https://clinicaltrials.gov/ct2/show/NCT04540419|dead-url=no}}</ref>，随后Petrovax获得政府批准，将其扩大到8,000名志愿者<ref>{{cite web|author=Bloomberg News|date=2020-11-25|title=Russia's Richest Man Seeks Global Market for Local Covid-19 Drug - BNN Bloomberg|url=https://www.bnnbloomberg.ca/russia-s-richest-man-seeks-global-market-for-local-covid-19-drug-1.1527470|access-date=2020-11-28|work=BNN|archive-date=2021-11-24|archive-url=https://web.archive.org/web/20211124152509/https://www.bnnbloomberg.ca/russia-s-richest-man-seeks-global-market-for-local-covid-19-drug-1.1527470|dead-url=no}}</ref><ref name=":11">{{cite news|author=Reuters Staff|date=2020-12-07|title=Russia approves clinical trials for Chinese COVID-19 vaccine Ad5-Ncov: Ifax|work=Reuters|url=https://ca.reuters.com/article/us-health-coronavirus-china-russia-idUSKBN28H0RN|access-date=2020-12-07|archive-date=2020-12-09|archive-url=https://web.archive.org/web/20201209075227/https://ca.reuters.com/article/us-health-coronavirus-china-russia-idUSKBN28H0RN|dead-url=no}}</ref>。

2020年10月，墨西哥收到第一批针对10,000至15,000名志愿者进行第三阶段试验的疫苗<ref>{{cite web|date=2020-11-03|title=México recibe el primer lote de la vacuna candidata de CanSino Biologics; alistan pruebas|url=https://elceo.com/internacional/mexico-recibe-el-primer-lote-de-la-vacuna-candidata-de-cansino-biologics-alistan-pruebas/|access-date=2020-11-03|work=EL CEO|language=es-MX|archive-date=2021-05-20|archive-url=https://web.archive.org/web/20210520005328/https://elceo.com/internacional/mexico-recibe-el-primer-lote-de-la-vacuna-candidata-de-cansino-biologics-alistan-pruebas/|dead-url=no}}</ref><ref name=":10">{{cite web|date=2020-11-10|title=Chinese Covid vaccine trials to be expanded to five more states|url=https://mexiconewsdaily.com/news/chinese-covid-vaccine-trials-to-be-expanded-to-five-more-states/|access-date=2020-11-11|work=Mexico News Daily|archive-date=2021-02-03|archive-url=https://web.archive.org/web/20210203091608/https://mexiconewsdaily.com/news/chinese-covid-vaccine-trials-to-be-expanded-to-five-more-states/|dead-url=no}}</ref>。

另外，巴基斯坦开始对40,000名志愿者进行三期临床试验<ref name=":1">{{cite web|title=Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above - Full Text View - ClinicalTrials.gov|url=https://clinicaltrials.gov/ct2/show/NCT04526990|access-date=2020-10-21|work=clinicaltrials.gov|archive-date=2020-09-18|archive-url=https://web.archive.org/web/20200918142722/https://clinicaltrials.gov/ct2/show/NCT04526990|dead-url=no}}</ref>。截至12月，约有13,000名志愿者参加试验<ref name=":4" />。

2020年11月，智利批准由La Frontera大学管理，针对5,200名志愿者的三期临床试验<ref name=":2">{{cite web|vauthors=Yáñez PL|date=2020-11-15|title=Así funcionan las cuatro vacunas que se probarán en Chile|url=https://www.latercera.com/que-pasa/noticia/asi-funcionan-las-cuatro-vacunas-que-se-probaran-en-chile/AD22DRDA4REH5MRWGIAI7GQFSM/|access-date=2020-11-17|work=La Tercera|archive-date=2020-12-24|archive-url=https://web.archive.org/web/20201224200607/https://www.latercera.com/que-pasa/noticia/asi-funcionan-las-cuatro-vacunas-que-se-probaran-en-chile/AD22DRDA4REH5MRWGIAI7GQFSM/|dead-url=no}}</ref><ref name=":9">{{cite web|title=Gob.cl - Article: Science Minister: "We Work With Maximum Rigor So That Science And Technology Benefit People'S Health"|url=https://www.gob.cl/en/news/science-minister-we-work-with-maximum-rigor-so-that-science-and-technology-benefit-peoples-health/|access-date=2020-11-21|work=Government of Chile|archive-date=2020-12-13|archive-url=https://web.archive.org/web/20201213233446/https://www.gob.cl/en/news/science-minister-we-work-with-maximum-rigor-so-that-science-and-technology-benefit-peoples-health/|dead-url=no}}</ref>。

2020年12月，阿根廷Hupedes基金会在布宜诺斯艾利斯和马德普拉塔市区的11个医疗中心开始三期临床试验<ref name=":0">{{cite web|date=2020-12-14|title=Comenzará en la Argentina un nuevo estudio de vacuna recombinante contra el SARS-CoV-2|url=https://www.infobae.com/america/tendencias-america/2020/12/14/comenzara-en-la-argentina-un-nuevo-estudio-de-vacuna-recombinante-contra-el-sars-cov-2/|access-date=2020-12-15|work=infobae|language=es-ES|archive-date=2021-03-23|archive-url=https://web.archive.org/web/20210323032318/https://www.infobae.com/america/tendencias-america/2020/12/14/comenzara-en-la-argentina-un-nuevo-estudio-de-vacuna-recombinante-contra-el-sars-cov-2/|dead-url=no}}</ref>。

=== 鼻喷雾剂一期临床试验 ===
与大多数需要肌肉注射的COVID-19候选疫苗相比，康希诺生物于2020年9月在中国开始对144名成年人进行一期临床试验，以确定该疫苗作为鼻喷雾剂给药的安全性和免疫原性<ref>{{cite web |title=A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults - Full Text View |url=https://clinicaltrials.gov/ct2/show/NCT04552366 |work=ClinicalTrials.gov |access-date=2020-09-25 |archive-date=2021-04-27 |archive-url=https://web.archive.org/web/20210427032639/https://clinicaltrials.gov/ct2/show/NCT04552366 |dead-url=no }}</ref>。2021年6月，陈薇在2021浦江创新论坛表示，雾化剂已经获中国大陆药监部门批准扩大临床试验，研发团队正在申请紧急使用<ref>{{cite news |author1=操秀英 |author2=刘垠 |title=陈薇院士：雾化吸入式新冠疫苗正在申请紧急使用 |url=http://www.chinanews.com/gn/2021/06-04/9492324.shtml |accessdate=2021-06-04 |work=科技日报 |agency=中新社 |publisher=中新网 |date=2021-06-04 |archive-date=2021-06-14 |archive-url=https://web.archive.org/web/20210614092535/http://www.chinanews.com/gn/2021/06-04/9492324.shtml |dead-url=no }}</ref>。

==安全性==
克威莎是腺病毒载体疫苗（类似英国AZ、美国J&J、俄国卫星五号），这种技术路线潜在的血栓诱发可能性一直为世界所关注。根据世卫组织2022年五月披露的统计，截止2021年年末，在全世界接种的5.8千万例疫苗（其中中国大陆仅1.38千万例其余均位于境外）中，共发生47例疫苗后TTS血栓，合十万分之0.081，远低于其余腺病毒载体疫苗的疫苗后TTS血栓发生率十万分之0.5~6.8。47例中27例为男性，另外，在已记录时间的34例TTS血栓中33例为疫苗注射后30日内发生。<ref>{{cite web |author1=世卫组织 |title=关于康希诺生物Ad5-nCoV-S新冠病疫苗（克威莎）的中期建议（中期指南） |url=https://apps.who.int/iris/rest/bitstreams/1424502/retrieve}}</ref>

==生产==
2020年2月，负责研发该疫苗的陈薇院士表示，Ad5-NCov的年生产能力到2021年将达到5亿剂<ref name=":16"/>。同年9月，俄罗斯Petrovax表示，一旦疫苗在俄罗斯获得批准，2020年俄罗斯将每月生产400万剂Ad5-NCov疫苗，2021年将每月生产1000万剂<ref name="Petrovax">{{cite web|date=2020-09-21|title=Russian Recruits Show 'No Side Effects' in Chinese Coronavirus Vaccine Trials|url=https://www.themoscowtimes.com/2020/09/21/russian-recruits-show-no-side-effects-in-chinese-coronavirus-vaccine-trials-a71501|access-date=2020-09-22|work=The Moscow Times|archive-date=2021-03-29|archive-url=https://web.archive.org/web/20210329061441/https://www.themoscowtimes.com/2020/09/21/russian-recruits-show-no-side-effects-in-chinese-coronavirus-vaccine-trials-a71501|dead-url=no}}</ref>。

2021年2月，墨西哥收到了第一批用于疫苗的活性成分，由Drugmex公司在[[克雷塔罗州|克雷塔罗州]]负责分装<ref>{{Cite news|last=Solomon|first=Daina Beth|date=2021-02-28|title=China's CanSino says first vaccines packaged in Mexico will be ready in March|work=Reuters|url=https://www.reuters.com/article/us-health-coronavirus-mexico-vaccine-idUSKCN2AS0P0|access-date=2021-03-12|archive-date=2021-05-15|archive-url=https://web.archive.org/web/20210515183952/https://www.reuters.com/article/us-health-coronavirus-mexico-vaccine-idUSKCN2AS0P0|dead-url=no}}</ref>。同年4月，马来西亚Solution Biologics宣布，将负责疫苗在马来西亚的分装，以进行分发<ref name=":3">{{Cite web|title=Malaysia to receive CanSino vaccine this month {{!}} The Malaysian Insight|url=https://www.themalaysianinsight.com/s/308349|access-date=2021-04-03|work=www.themalaysianinsight.com|language=en|archive-date=2021-05-14|archive-url=https://web.archive.org/web/20210514171531/https://www.themalaysianinsight.com/s/308349|dead-url=no}}</ref>。

==获批和供应==
===亚洲===
====中国大陆====
{{seealso|中国大陆2019冠状病毒病疫苗接种计划}}
2020年6月25日，Ad5-nCoV疫苗获得中华人民共和国[[中央军委后勤保障部卫生局|中央军委后勤保障部卫生局]]颁发的军队特需药品批件，有效期一年<ref>{{cite news |title=康希诺新冠疫苗已获批军队内部使用 完成II期临床揭盲 |url=https://finance.sina.com.cn/chanjing/cyxw/2020-06-29/doc-iirczymk9462086.shtml |accessdate=2021-04-07 |work=新浪财经综合 |date=2020-06-29}}</ref>。2021年2月21日，康希诺生物向中华人民共和国国家药监局提交附条件上市申请<ref>{{cite news |author1=李潇潇 |title=陈薇院士团队与康希诺生物新冠疫苗附条件上市申请获受理 |url=https://finance.sina.com.cn/chanjing/cyxw/2021-02-24/doc-ikftpnny9437688.shtml |accessdate=2021-02-24 |work=澎湃新闻 |date=2021-02-24 |archive-date=2021-08-19 |archive-url=https://web.archive.org/web/20210819070230/https://finance.sina.com.cn/chanjing/cyxw/2021-02-24/doc-ikftpnny9437688.shtml |dead-url=no }}</ref>，2月25日获国家药监局附条件批准注册申请<ref>{{cite news|url=http://news.cri.cn/20210225/db2cd084-91cc-b0d7-c1d0-a2802309ef33.html|title=国家药监局附条件批准两家公司新冠疫苗注册申请|publisher=中央广电总台央视新闻客户端|date=2021-02-25|accessdate=2021-02-25|archive-date=2021-08-17|archive-url=https://web.archive.org/web/20210817213505/http://news.cri.cn/20210225/db2cd084-91cc-b0d7-c1d0-a2802309ef33.html|dead-url=no}}</ref>。2021年4月4日[[云南省|云南省]][[瑞丽市|瑞丽市]]发生疫情后，15万剂“克威莎”腺病毒载体疫苗陆续抵达云南，将助力[[德宏州|德宏州]]包括瑞丽市在内的广大边境地区民众尽快完成疫苗接种<ref>{{cite news |title=15万剂康希诺疫苗抵滇，专家：单针接种可帮瑞丽迅速建免疫屏障 |url=http://news.yunnan.cn/system/2021/04/04/031374593.shtml |accessdate=2021-04-04 |work=环球时报环球网 |date=2021-04-04}}</ref>。2021年5月，浙江省开始进行“克威莎”腺病毒载体疫苗的接种工作<ref>{{cite news|url=http://www.hangzhou.gov.cn/art/2021/5/14/art_1228998462_59034850.html|title=陈薇院士牵头研发，浙江多地到货单针接种的新冠病毒疫苗…三种疫苗如何选？|publisher=浙江新闻|date=2021-05-14|accessdate=2021-05-14|archive-date=2021-05-15|archive-url=https://web.archive.org/web/20210515144714/http://www.hangzhou.gov.cn/art/2021/5/14/art_1228998462_59034850.html|dead-url=no}}</ref>，上海市也于同月13日开始供应此种腺病毒载体疫苗<ref>{{cite news|url=http://health.cnr.cn/yg/20210517/t20210517_525488263.shtml|title=上海：启动76岁及以上人群新冠疫苗接种 一针剂疫苗已开始使用|publisher=央广网|date=2021-05-17|accessdate=2021-05-19|archive-date=2021-05-19|archive-url=https://web.archive.org/web/20210519145504/http://health.cnr.cn/yg/20210517/t20210517_525488263.shtml|dead-url=no}}</ref>。而在北京市，4月21日即有接种点开始供应腺病毒载体疫苗，但截至5月19日仍然仅海淀区内个别接种点（仅10个）供应该疫苗，选择接种该疫苗的也多为工作时间紧凑或有出差、出游安排的年轻人<ref>{{cite news|url=https://www.chinanews.com/sh/2021/05-20/9481226.shtml|title=10处新冠肺炎疫苗接种点提供“一针疫苗”接种服务 海淀“一针疫苗”累计接种7028支|work=[[北京青年报|北京青年报]]|date=2021-05-20|accessdate=2021-05-21|archive-date=2021-05-21|archive-url=https://web.archive.org/web/20210521030323/https://www.chinanews.com/sh/2021/05-20/9481226.shtml|dead-url=no}}</ref>。截至2021年5月，中国大陆已有15个一级行政区采购了该疫苗<ref>{{cite news |title=多地开打“一针苗” 约1000万人已接种 |url=http://finance.eastmoney.com/a/202105251935177473.html |accessdate=2021-05-25 |work=羊城晚报 |date=2021-05-25 |archive-date=2021-05-25 |archive-url=https://web.archive.org/web/20210525151007/http://finance.eastmoney.com/a/202105251935177473.html |dead-url=no }}</ref>。

2021年12月，克威莎疫苗开始在位于[[上海市|上海市]][[宝山区_(上海市)|宝山区]]的厂房投产，该厂由[[上海医药|上海医药]]以上海三维生物技术有限公司作为投资主体，与康希诺生物、上海生物医药产业股权投资基金合伙企业合资组建<ref>{{cite news |author1=唐闻佳 |title=“克威莎”来了！第一批“上海产”新冠疫苗诞生 |url=http://www.ce.cn/cysc/yy/hydt/202112/15/t20211215_37172474.shtml |accessdate=2021-12-19 |work=文汇报 |date=2021-12-15 |archive-date=2021-12-15 |archive-url=https://web.archive.org/web/20211215021911/http://www.ce.cn/cysc/yy/hydt/202112/15/t20211215_37172474.shtml |dead-url=no }}</ref>。2022年1月27日，上藥康希諾寶山工廠新冠疫苗正式在上海量產上市。<ref>{{cite news |title=國內唯一一款單針新冠疫苗在上海量產上市 |url=http://sh.people.com.cn/BIG5/n2/2022/0127/c134768-35115768.html |accessdate=2022-01-27 |archive-date=2022-01-27 |archive-url=https://web.archive.org/web/20220127103404/http://sh.people.com.cn/BIG5/n2/2022/0127/c134768-35115768.html |dead-url=no }}</ref>

====其他地方====
2020年10月，印度尼西亚与康希诺生物达成协议，将在2020年11月交付10万剂疫苗，并期望在2021年再交付1500至2000万剂疫苗<ref>{{cite web |vauthors=Taufiqurrahman M |title=Indonesia can be manufacutring hub for COVID-19 vaccine, says Chinese foreign minister |url=https://www.thejakartapost.com/news/2020/10/12/indonesia-can-be-manufacturing-hub-for-covid-19-vaccine-says-chinese-foreign-minister.html |publisher=Jakarta Post |access-date=2020-10-13 |archive-date=2020-12-31 |archive-url=https://web.archive.org/web/20201231080441/https://www.thejakartapost.com/news/2020/10/12/indonesia-can-be-manufacturing-hub-for-covid-19-vaccine-says-chinese-foreign-minister.html |dead-url=no }}</ref>。2021年1月，康希诺生物向巴基斯坦提供了2000万剂疫苗<ref name=":6">{{Cite web|last=News|first=Bloomberg|date=2021-01-22|title=China Vaccine Maker CanSino to Offer Pakistan 20 Million Doses - BNN Bloomberg|url=https://www.bnnbloomberg.ca/china-vaccine-maker-cansino-to-offer-pakistan-20-million-doses-1.1552360|access-date=2021-01-26|work=BNN|archive-date=2021-01-22|archive-url=https://web.archive.org/web/20210122123208/https://www.bnnbloomberg.ca/china-vaccine-maker-cansino-to-offer-pakistan-20-million-doses-1.1552360|dead-url=no}}</ref>，并于2月12日批准了该疫苗的紧急使用。前300万剂将于4月到达<ref name=":15">{{Cite news|last=Shahzad|first=Asif|date=2021-02-12|title=Pakistan approves Chinese CanSinoBIO COVID vaccine for emergency use|work=Reuters|url=https://www.reuters.com/article/us-health-coronavirus-pakistan-vaccine-idUSKBN2AC1FG|access-date=2021-02-12|archive-date=2021-06-18|archive-url=https://web.archive.org/web/20210618111251/https://www.reuters.com/article/us-health-coronavirus-pakistan-vaccine-idUSKBN2AC1FG|dead-url=no}}</ref>。2021年2月，马来西亚Solution Biologics公司同意向政府提供350万剂疫苗<ref>{{Cite news|last=Staff|first=Reuters|date=2021-02-04|title=Malaysia's Solution Group to supply 3.5 million doses of CanSino vaccine to government|work=Reuters|url=https://www.reuters.com/article/us-health-coronavirus-malaysia-idUSKBN2A41I2|access-date=2021-02-04|archive-date=2021-03-02|archive-url=https://web.archive.org/web/20210302181222/https://www.reuters.com/article/us-health-coronavirus-malaysia-idUSKBN2A41I2|dead-url=no}}</ref>。政府于同年4月起先交付50万剂，其余的全部由Solution Biologics完成<ref name=":3" />。

===欧洲===
2021年3月，匈牙利批准该疫苗的紧急使用授权<ref name="Ashok">{{Cite news|last=Ashok|first=Rashmi|date=2021-03-22|title=UPDATE 2-China's CanSino Biologics COVID-19 vaccine receives emergency use approval in Hungary|work=Reuters|url=https://www.reuters.com/article/health-coronavirus-cansinobio-hungary-idUSL1N2LK00K|access-date=2021-03-22|archive-date=2021-03-23|archive-url=https://web.archive.org/web/20210323120030/https://www.reuters.com/article/health-coronavirus-cansinobio-hungary-idUSL1N2LK00K|dead-url=no}}</ref>。

===北美洲===
2020年12月，墨西哥外交部长{{le|马塞洛·埃布拉德|Marcelo Ebrard}}与康希诺生物签署协议，同意提供3500万剂疫苗<ref>{{cite news|author=Reuters Staff|date=2020-12-10|title=Mexico agrees to buy 35 million doses of CanSino COVID vaccine|work=Reuters|url=https://www.reuters.com/article/us-health-coronavirus-mexico-cansino-idUSKBN28K0BT|access-date=2020-12-10|archive-date=2021-06-22|archive-url=https://web.archive.org/web/20210622091758/https://www.reuters.com/article/us-health-coronavirus-mexico-cansino-idUSKBN28K0BT|dead-url=no}}</ref>。2021年2月10日，墨西哥卫生监管机构Cofepris批准该疫苗用于紧急使用授权<ref name=":14">{{cite news|date=10 February 2021|title=Mexico approves China's CanSino and Sinovac COVID-19 vaccines|work=Reuters|url=https://www.reuters.com/article/health-coronavirus-mexico-cansino/update-2-mexico-approves-chinas-cansino-and-sinovac-covid-19-vaccines-idUSL1N2KG0NO|accessdate=2021-04-08|archive-date=2021-03-02|archive-url=https://web.archive.org/web/20210302130631/https://www.reuters.com/article/health-coronavirus-mexico-cansino/update-2-mexico-approves-chinas-cansino-and-sinovac-covid-19-vaccines-idUSL1N2KG0NO|dead-url=no}}</ref>。墨西哥已接收200万剂疫苗的有效成分，预计将在2月份接收600万剂<ref>{{Cite news|last=Reuters|first=|date=2021-02-11|title=UPDATE 2-'Our gratitude always': From China's CanSino, Mexico welcomes biggest vaccine shipment yet|work=Reuters|url=https://www.reuters.com/article/health-coronavirus-mexico-vaccine-idUKL1N2KH1H2|access-date=2021-02-11|archive-date=2021-06-12|archive-url=https://web.archive.org/web/20210612063519/https://www.reuters.com/business/healthcare-pharmaceuticals/our-gratitude-always-chinas-cansino-mexico-welcomes-biggest-vaccine-shipment-yet-2021-02-11/|dead-url=no}}</ref>。

===南美洲===
2021年3月，智利签署协议，将在当年5月和6月交付180万剂疫苗<ref>{{Cite news|last=Sherwood|first=Dave|date=2021-03-30|title=Chile inks deal for 1.8 million doses of CanSino COVID-19 vaccine as inoculation drive plows ahead|language=en|work=Reuters|url=https://www.reuters.com/article/us-health-coronavirus-chile-vaccine-idUSKBN2BM2HM|access-date=2021-03-30|archive-date=2021-04-02|archive-url=https://web.archive.org/web/20210402023547/https://www.reuters.com/article/us-health-coronavirus-chile-vaccine-idUSKBN2BM2HM|dead-url=no}}</ref>。该疫苗于2021年4月获得紧急使用授权<ref name=":7">{{Cite web|title=ISP Approves Emergency Use And Importation Of Cansino Vaccine To Fight COVID-19|url=https://www.ispch.cl/noticia/isp-aprueba-uso-de-emergencia-e-importacion-de-la-vacuna-covid-19-de-laboratorio-cansino/|access-date=2021-04-08|work=Institute of Public Health of Chile|archive-date=2021-04-18|archive-url=https://web.archive.org/web/20210418054338/https://www.ispch.cl/noticia/isp-aprueba-uso-de-emergencia-e-importacion-de-la-vacuna-covid-19-de-laboratorio-cansino/|dead-url=no}}</ref>。

== 参考文献 ==
{{Reflist|35em}}

{{-}}
{{2019冠状病毒病中国大陆疫情}}
{{疫苗}}

[[Category:腺病毒科|Category:腺病毒科]]
[[Category:临床试验|Category:临床试验]]
[[Category:中国大陆2019冠状病毒病疫苗|Category:中国大陆2019冠状病毒病疫苗]]
[[Category:2020年面世的產品|Category:2020年面世的產品]]
[[Category:中国人民解放军军事科学院军事医学研究院|Category:中国人民解放军军事科学院军事医学研究院]]
[[Category:中华人民共和国医疗|Category:中华人民共和国医疗]]
[[Category:病毒载体疫苗|Category:病毒载体疫苗]]